Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., a subsidiary of ABL Diagnostics (FR001400AHX6 – ABLD), a publicly listed company on Euronext, has announced the opening of a new temperature-controlled warehouse in the USA on Tuesday, February 20, 2024. This move is part of the company’s commitment to providing its clients and partners with improved quality and speed of service.
The new warehouse, located in New Jersey, was established through a Logistics and Warehousing Agreement between AdvancedDx Biological Laboratories USA Inc. and VELA Diagnostics USA Inc. The warehouse offers a high-level logistics service specializing in the warehousing and transportation of biomedical, general laboratory products, and medical devices to research laboratories and hospitals, in compliance with Good Distribution Practices (GDP).
Ronan Boulme, ABL Diagnostics GRC Director, expressed the significance of the new warehouse for AdvancedDx Biological Laboratories USA Inc., stating, “This brand new warehouse consolidates our presence in the USA and underlines our constant commitment to providing clients and partners with an excellent service dedicated exclusively to the healthcare sector.”
Sam Dajani, Chairman & Chief Executive Officer at Vela Operations Singapore Pte. Ltd., also commented on the agreement, saying, “Through this Logistics and Warehousing Agreement, we initiate an important move with ABL Diagnostics, which has the potential to strengthen the relationship between both companies globally.”
AdvancedDx Biological Laboratories USA Inc. is a subsidiary of ABL Diagnostics S.A. (ABLD), a leading international company in molecular biology assays and software for genotyping through DNA sequencing – DeepChek®. ABL Diagnostics, based in Woippy, is listed on Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). The company’s products generate recurring revenues and cover one of the largest portfolios of microbiology applications. ABL Diagnostics distributes its products globally through its sales team and a network of exclusive distributors on all continents. Its clients include academic laboratories, private laboratories, and researchers looking to implement innovative and robust microbiology contents.
Vela Diagnostics, a leading provider of integrated IVD system solutions from sample to result, was also involved in the establishment of the new warehouse. VELA’s test solutions utilize the automated Sentosa platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.
© 2023 Vela Diagnostics Holding Pte Ltd. All rights reserved. Sentosa® is a registered trademark of Vela Diagnostics Holding Pte Ltd outside Singapore in several markets including the US, EU, PRC, and the UK. All Sentosa products listed above are by Vela Diagnostics.
For more information, please visit www.abldiagnostics.com or contact ABL Diagnostics General Manager, Chalom Sayada, at +33 7 83 64 68 50 or info@abldiagnostics.com.
To learn more about Vela Diagnostics, contact Lucia Vira at lucia.vira@veladx.com.
This press release contains forward-looking statements concerning ABL Diagnostics and its business. These statements are based on reasonable assumptions but are subject to numerous risks, including those set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022, under number 22-296, available on the ABL Diagnostics website (www.abldiagnostics.com). Economic conditions, financial markets, and the markets in which ABL Diagnostics operates can also affect the accuracy of these statements. The occurrence of these risks could result in materially different results, financial conditions, performance, or achievements for ABL Diagnostics.
This press release does not constitute an offer or invitation to sell or subscribe for ABL Diagnostics shares in any country. Distribution of this press release may be prohibited by applicable laws. Persons in possession of this press release should inquire about any local restrictions and comply with them.
Distributed by https://pressat.co.uk/
